We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the completed initiation of all clinical trial centers. Read more!
Update on priMe study
TB vaccine candidate being investigated to prevent TB infection in infants in Phase III priMe study. Read more!
First clinical center in South Africa initiated for a Pan-African phase III trial against tuberculosis
Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 – in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.
Press release on VPM’s COVID-19 study published in “Neue Presse”
“MHH testet Corona-Impfstoff – besser als Biontech & Co.?”
First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting
Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled
Tdap study enters phase III
Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week,
30 Million Euro Loan from the EIB for TB
VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa.
Hope for the elderly in the corona pandemic
First participants receive VPM1002 in a late-stage phase III clinical trial in Germany.
SARS-CoV-2 study kicks off in Germany
First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic.
Immune boost against the corona virus
In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus.